July 4, 2022

Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2021

The company has released voluntary disclosures since 2015 in accordance with the EFPIA Code of Practice


  • In line with its commitment to transparency, Grifols has disclosed for the seventh consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA’s scope, including Spain.
  • In 2021, Grifols made transfers of value in Europe amounting to Euro 18.9 million. This 41% increase compared to 2020 is mainly due to two factors:
  1. Larger investments in studies related to, among other areas, the SARS-CoV-2 virus, which resulted in a 38% increase in transfers of value related to R&D compared to 2020. They amounted to Euro 15.6 million, representing 83% of the total.
  2. The progressive recovery of face-to-face interactions with healthcare organizations and healthcare professionals at scientific events, which have returned to similar pre-pandemic levels.
  • These two factors also explain the evolution registered in Spain. Transfers of value increased 78% to Euro 12.9 million. Those related to R&D accounted for 94% of the total amount and stood at Euro 12.2 million.
  • Spain generated 68% of the group’s total transfers in Europe in 2021 and 78% of those related to R&D.
  • In 2021, Grifols made transfers of value to 194 healthcare professionals in Spain that amounted to Euro 156,874 (Euro 153,425 in 2020) and 47 healthcare organizations, which totaled Euro 556,378 (Euro 436,969 in 2020).
  • The EFPIA Code of Practice, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to all the company’s divisions.
  • In addition to Europe, Grifols applies this policy of transparency to the United States as required by the regulatory body (Centers for Medicare & Medicaid Services, CMS).
  • All related information is public and available on the Grifols corporate website: www.grifols.com

Information Published in Accordance with the EFPIA Code of Practice

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities; and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.